Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck

Shuang Cai; Yumei Xie; Neal M. Davies; Mark S. Cohen; M. Laird Forrest

doi:10.4155/tde.10.38

Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck

Shuang Cai, Yumei Xie, Neal M. Davies, Mark S. Cohen, M. Laird Forrest

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Since head and neck squamous cell carcinoma (HNSCC) preferentially metastasizes to the locoregional lymphatics, treatment of the tumor-draining cervical lymph nodes is paramount. Results: We developed a hyaluronan-cisplatin (HA-Pt) nanoconjugate with prolonged lymphatic retention and greatly improved tumor tissue deposition for the treatment of metastatic HNSCC. We also developed an orthotopic metastatic xenograft model of HNSCC to examine the efficacy of the nanoconjugate. HNSCC (1/week × 3 weeks) were completely cured for 57% of the female mice in the HA-Pt treatment group, which demonstrated greatly hindered HNSCC progression compared with the standard cisplatin therapy (p < 0.05). Conclusion: With this insight, we will be able to optimize the carriers for better uptake, penetration and retention within cancer cells.

Original language	English (US)
Pages (from-to)	237-245
Number of pages	9
Journal	Therapeutic Delivery
Volume	1
Issue number	2
DOIs	https://doi.org/10.4155/tde.10.38
State	Published - Aug 2010
Externally published	Yes

ASJC Scopus subject areas

Pharmaceutical Science

Online availability

10.4155/tde.10.38

Library availability

Discover UIUC Full Text

Cite this

@article{9a211f2e44204fa68146f53564c5de96,

title = "Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck",

abstract = "Background: Since head and neck squamous cell carcinoma (HNSCC) preferentially metastasizes to the locoregional lymphatics, treatment of the tumor-draining cervical lymph nodes is paramount. Results: We developed a hyaluronan-cisplatin (HA-Pt) nanoconjugate with prolonged lymphatic retention and greatly improved tumor tissue deposition for the treatment of metastatic HNSCC. We also developed an orthotopic metastatic xenograft model of HNSCC to examine the efficacy of the nanoconjugate. HNSCC (1/week × 3 weeks) were completely cured for 57% of the female mice in the HA-Pt treatment group, which demonstrated greatly hindered HNSCC progression compared with the standard cisplatin therapy (p < 0.05). Conclusion: With this insight, we will be able to optimize the carriers for better uptake, penetration and retention within cancer cells.",

author = "Shuang Cai and Yumei Xie and Davies, {Neal M.} and Cohen, {Mark S.} and Forrest, {M. Laird}",

year = "2010",

month = aug,

doi = "10.4155/tde.10.38",

language = "English (US)",

volume = "1",

pages = "237--245",

journal = "Therapeutic Delivery",

issn = "2041-5990",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck

AU - Cai, Shuang

AU - Xie, Yumei

AU - Davies, Neal M.

AU - Cohen, Mark S.

AU - Forrest, M. Laird

PY - 2010/8

Y1 - 2010/8

N2 - Background: Since head and neck squamous cell carcinoma (HNSCC) preferentially metastasizes to the locoregional lymphatics, treatment of the tumor-draining cervical lymph nodes is paramount. Results: We developed a hyaluronan-cisplatin (HA-Pt) nanoconjugate with prolonged lymphatic retention and greatly improved tumor tissue deposition for the treatment of metastatic HNSCC. We also developed an orthotopic metastatic xenograft model of HNSCC to examine the efficacy of the nanoconjugate. HNSCC (1/week × 3 weeks) were completely cured for 57% of the female mice in the HA-Pt treatment group, which demonstrated greatly hindered HNSCC progression compared with the standard cisplatin therapy (p < 0.05). Conclusion: With this insight, we will be able to optimize the carriers for better uptake, penetration and retention within cancer cells.

AB - Background: Since head and neck squamous cell carcinoma (HNSCC) preferentially metastasizes to the locoregional lymphatics, treatment of the tumor-draining cervical lymph nodes is paramount. Results: We developed a hyaluronan-cisplatin (HA-Pt) nanoconjugate with prolonged lymphatic retention and greatly improved tumor tissue deposition for the treatment of metastatic HNSCC. We also developed an orthotopic metastatic xenograft model of HNSCC to examine the efficacy of the nanoconjugate. HNSCC (1/week × 3 weeks) were completely cured for 57% of the female mice in the HA-Pt treatment group, which demonstrated greatly hindered HNSCC progression compared with the standard cisplatin therapy (p < 0.05). Conclusion: With this insight, we will be able to optimize the carriers for better uptake, penetration and retention within cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=79954990663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954990663&partnerID=8YFLogxK

U2 - 10.4155/tde.10.38

DO - 10.4155/tde.10.38

M3 - Article

C2 - 21339844

AN - SCOPUS:79954990663

SN - 2041-5990

VL - 1

SP - 237

EP - 245

JO - Therapeutic Delivery

JF - Therapeutic Delivery

IS - 2

ER -

Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck

Abstract

ASJC Scopus subject areas

Online availability

Library availability

Related links

Fingerprint

Cite this